Globe Newswire
Globe Newswire
More Globe Newswire
View Older Stories View Newer Stories-
Integral Metals Provides 2025 Year-in-Review and Outlines 2026 Exploration Plans
-
Cadrenal Therapeutics Highlights High Incidence of Thrombotic Complications in Heparin-Induced Thrombocytopenia (HIT) at the J.P. Morgan Healthcare Conference and VLX-1005 as a Potential Therapeutic S
-
Enphase Energy Begins Shipments of IQ9 Commercial Microinverters in the United States
-
ZAGG Honored with Consumer Electronics Industry Performance Award from Circana
-
NDT Pharmaceuticals, Inc.’s wholly owned subsidiary, Good Salt Life, Inc., Advances into AI-Robotics for Unmanned Hospital Disinfection
-
PensionBee Launches on SS&C’s RolloverCentral®, Offering 1% Match on All Rollovers and Contributions
-
Vortex Expands into Cincinnati, Ohio – Now Offering Expert Commercial Door Services
-
John Osborn Joins SeenThis as President US
-
AmpliTech Group Receives over $9 million for its $4 Unit Subscription Rights Offering
-
IN8bio Presents Updated Phase I/II Data Demonstrating Meaningful and Durable Survival Improvements in Newly Diagnosed Glioblastoma
-
Safe-Pro USA to Showcase New NIJ 0101.07 Government Certification-Ready High Performance Body Armor Plates & Innovative RAPID Series Ballistic Shield at SHOT Show 2026
-
Praxis Precision Medicines Enters Its Next Chapter Following a Pivotal Year of Progress
-
Hylaine Appoints Former NTT DATA Executive Doug Hautop as President
-
Copper Quest and i2i Enter Into Corporate Marketing and Investor Awareness Agreement
-
Breakthrough Study Shows Cognitive Training Improves Resilience for Warfighters
-
MDxHealth Reports Preliminary Fourth Quarter and Full Year 2025 Revenues, Issues 2026 Revenue Guidance, and Amends Earnout Terms with Exact Sciences
-
CVRx Reports Preliminary Fourth Quarter and Fiscal Year 2025 Financial Results and Issues Fiscal 2026 Guidance
-
Abercrombie & Fitch Co. Provides Fourth Quarter and Fiscal Year Outlook Update
-
Cogent Biosciences Announces Anticipated 2026 Commercial and Clinical Milestones for Bezuclastinib and Precision Therapies Portfolio
-
NIMA Partners Introduces the Next-Generation NIMA Gluten Sensor with 99% Accuracy Across All Major Gluten Sources
-
Prestige Consumer Healthcare Announces Fiscal 2026 Third Quarter Earnings Results Date and Participation in the ICR Conference
-
Multi Ways Holdings Announces $6.4 Million Purchase of 62 Sinotruk Vehicles and Enters into Dealership Agreement with Cycle & Carriage
-
Biomea Fusion Enters 2026 Focused on Executing Key Icovamenib and BMF-650 Milestones
-
Kahuna Labs Highlights New Constellation Research Report on Frontline Productivity and the Future of AI-Driven Decision Velocity
-
WEBUY GLOBAL LTD. Expands Second Collaboration with CTG MICE Service Company Limited on AI Travel Devices
-
Profound Surpasses 2025 TULSA-PRO® Installed Base Goal
-
Bakkt Agrees to Acquire Distributed Technologies Research Ltd.
-
Mereo BioPharma Provides Corporate Update
-
Bionano Reports Preliminary Fourth Quarter and Full-Year 2025 Results
-
Legend Biotech Highlights Recent Business Updates at 44th Annual J.P. Morgan Healthcare Conference
-
Payment Outages Threaten $44.4 Billion in U.S. Retail & Hospitality Sales Annually
-
Senseonics Announces Preliminary Unaudited Revenue for Fourth Quarter 2025 and Provides Business Update
-
The Oncology Institute Reaffirms 2025 Guidance and Provides Preliminary 2026 Outlook
-
Xanadu Strengthens Executive Leadership with Appointment of Chief Financial Officer and Chief Legal Officer
-
Greystone Logistics, Inc. - Schedule of Events Regarding Earnings
-
Progyny to Discuss Updated Financial Expectations at Upcoming JP Morgan Healthcare Conference
-
zSpace and AIM Academy Showcase How Immersive AR/VR Learning Empowers Neurodivergent Students Ahead of FETC 2026
-
Hyperion DeFi Issues Letter to Shareholders
-
Zoom reinforces commitment to AI literacy with national student learning experience
-
Connect Biopharma Highlights New Mechanism of Action Data for Rademikibart and Outlines Priorities for 2026
-
Bicara Therapeutics Announces Phase 3 Optimal Dose and Provides 2026 Corporate Outlook
-
Kyverna Therapeutics Provides Corporate Update and Outlines 2026 Strategic Priorities at the J.P. Morgan Healthcare Conference
-
New Data Underscoring Ability of Leapfrog Bio’s OncoSLX Platform to Identify Drug Retargeting Opportunities for Treating Cancer Published in Nature Portfolio Journal
-
Genius Group Sets ERL Share Count Date for February 13, 2026
-
Arcadia Biosciences (RKDA) Announces Exercise of Preferred Investment Options for $2.1 Million Gross Proceeds
-
Safe-Pro USA to Showcase New NIJ 0101.07 Government Certification-Ready High Performance Body Armor Plates & Innovative RAPID Series Ballistic Shield at SHOT Show 2026
-
Satellogic Signs $18MM USD Agreement with Portugal to Deliver Two Mark V High-Resolution Satellites
-
Cabaletta Bio Announces 2026 Strategic Priorities
-
Netcapital to Tokenize Hydrogen Drilling Assets
-
Zapata and University of Maryland Collaborate to Advance New Paradigm in Quantum Software
